洁瑞品牌怎么样 申请店铺

我要投票 洁瑞在医疗器械行业中的票数:780 更新时间:2026-02-16
洁瑞是哪个国家的品牌?「洁瑞」是 山东威高集团医用高分子制品股份有限公司 旗下著名品牌。该品牌发源于山东,由创始人张华威在2000-12-28期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力洁瑞品牌出海!将品牌入驻外推网,定制洁瑞品牌推广信息,可以显著提高洁瑞产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

洁瑞怎么样

山东威高集团医用高分子制品股份有限公司(「本公司」)及其附属公司(「本集团」)主要从事研发、生产及销售医用耗材、骨科材料、心脏支架等。本公司为国家高技术研究发展(863)计划成果产业化基地、国家级高新技术企业。本集团主要生产基地位于山东省威海市。

本集团在中国注册,拥有一个由18个销售办事处及21个客户联络中心和107多家城市代表处组成的庞大销售网络,并已建立广泛的客户基础,其产品销售予5,400多家医疗单位和分销商,其中包括医院2800多家、血站400多家、其它医疗单位700多家和逾1,500家贸易公司。

本集团生产的产品种类多达150余种,产品规格超过5000种,产品可分为六大系列,即1)一次性使用医疗耗材及原料,其中包括输液(血)器、注射器、血袋与血液成份分离耗材、采血系列耗材、齿科耗材和麻醉系列耗材等,以及医用PVC粒料和非PVC粒料等;2)骨科材料及工具,主要包括钢板、螺钉等创伤治疗耗材、脊柱系列耗材及正在发展的人工关节系列耗材;3)医用针制品,主要包括静脉针、注射针、留置针、采血针、异形针等系列制品;4)血液净化系列耗材,主要包括穿刺针、血液回路管、透析器等肾科耗材,以及用于红斑狼疮、器官移植排异反应、类风湿关节炎等免疫系统疾病治疗的免疫吸附柱,以及其它正在研发和注册的LDL吸附柱、内毒素吸附柱和乙肝病毒吸附柱等;5)心脏支架产品,主要包括药物涂层心脏支架、球囊等;6)用于药品包装的预充式注射器。

“国家高技术研究发展(863)计划成果产业化基地”、“国家级企业技术中心”,并建有企业博士后工作站。公司积极开展产、学、研合作,与中科院长春应用化学研究所、中科院大连化学物理研究所、中科院沈阳金属研究所、第三军医大学、301医院、哈工大(威海)等科研院所、院校紧密合作,并聘请了10位两院院士做顾问,依托其人才和科研力量,异地建立了九个威高集团研发中心,立足行业制高点,消化吸收国际前沿技术,开发具有自主知识产权的高科技产品。公司有60多个产品达到国内外先进水平,不少产品填补了国内空白,20个产品入选国家863计划、国家重点火炬计划、国家高技术产业示范化工程、国家级重点新产品等国家各类项目,其中药物涂层支架系统、预充式注射器、骨科植入材料等产品打破了国外公司对中国市场的垄断。

集团注重产品品牌的长远发展,强调其产品质量。自2001年11月以来,集团的一次性使用无菌输液器、一次性使用无菌输血器及一次性使用无菌注射器的生产及服务的质量体系获中国医疗器械质量认证中心授予ISO9001:2000认证、中国CMD认证。从1999年12月,集团的输液器、输血器、一次性使用注射器及塑料血袋等产品种类获得由TÜVProductServiceGmbh颁发的CE认证证书以来,本集团已先后获得一次性使用自动取血器、一次性使用CT增强注射器造影剂针筒、一次性使用自毁式安全注射器、自动缩回式安全注射器、骨科器械、金属接骨板,脊柱内固定系统,金属接骨螺钉、带锁髓内钉、一次性使用无菌注射针、一次性使用静脉留置针、无针密闭输液接头等产品及体系的CE认证。于2003年12月5日,集团的产品质量检查中心获中国实验室国家认可委员会评为符合国家测试及定标规定。于2005年6月23日,集团拥有的商标被中国国家工商行政管理总局认定为中国国内医疗器械行业第一个中国驰名商标。

目前,集团的销售主要在中国市场,本集团正积极开拓国际市场,产品已经出口美国、德国、罗马尼亚、澳大利亚和英国等30个国家和地区。

Shandong Weigao group medical polymer products Co., Ltd. (the "company") and its subsidiaries (the "group") are mainly engaged in research and development, production and sales of medical consumables, orthopedic materials, heart stents, etc. The company is the industrialization base of national high-tech research and development (863) plan achievement and national high-tech enterprise. The main production base of the group is located in Weihai City, Shandong Province. Registered in China, the group has a huge sales network consisting of 18 sales offices, 21 customer contact centers and 107 city representative offices, and has established a wide customer base. Its products are sold to more than 5400 medical units and distributors, including more than 2800 hospitals, more than 400 blood stations, more than 700 other medical units and more than 1500 trading companies. The group produces more than 150 kinds of products with more than 5000 specifications, which can be divided into six series, i.e. 1) disposable medical consumables and raw materials, including infusion (blood) devices, syringes, blood bag and blood component separation consumables, blood collection consumables, dental consumables and anesthesia consumables, as well as medical PVC granules and non PVC granules; 2) orthopedic materials And tools, mainly including steel plate, screw and other trauma treatment consumables, spine series consumables and developing artificial joint series consumables; 3) medical needle products, mainly including vein needle, injection needle, retention needle, blood sampling needle, abnormal needle and other series products; 4) blood purification series consumables, mainly including puncture needle, blood circuit tube, dialyzer and other renal consumables, as well as for erythema Immunosorbent columns for the treatment of immune system diseases such as lupus, organ transplantation rejection, rheumatoid arthritis, and other LDL, endotoxin and hepatitis B virus adsorption columns under development and registration; 5) cardiac stent products, mainly including drug coated cardiac stent, balloon, etc.; 6) pre filled syringes for drug packaging. "National High Tech Research and development (863) plan achievement industrialization base", "national enterprise technology center", and built enterprise postdoctoral workstation. The company actively carries out cooperation in production, learning and research, closely cooperates with Changchun Institute of Applied Chemistry of Chinese Academy of Sciences, Dalian Institute of Chemical Physics of Chinese Academy of Sciences, Shenyang Institute of metals of Chinese Academy of Sciences, the Third Military Medical University, 301 Hospital, Harbin University of Technology (Weihai) and other scientific research institutes and colleges, and employs 10 academicians of the two academies as consultants. Relying on their talents and scientific research forces, the company has established nine Weiwei in different places High Tech Group R & D center, based on the industry commanding point, digests and absorbs international cutting-edge technology, and develops high-tech products with independent intellectual property rights. More than 60 products of the company have reached the advanced level at home and abroad, and many products have filled in the gaps at home. 20 products have been selected into various national projects such as the National 863 plan, the national key torch plan, the national high-tech industrial demonstration project, and the national key new products, among which drug coated stent system, pre filled syringe, orthopedic implant materials and other products have broken the foreign companies' commitment to China Market monopoly. The group pays attention to the long-term development of the product brand and emphasizes its product quality. Since November 2001, the group's quality system for the production and service of disposable sterile infusion sets, disposable sterile infusion sets and disposable sterile syringes has been awarded ISO9001:2000 certification and China CMD certification by China Medical Device Quality Certification Center. Since December 1999, the group's infusion sets, blood transfusion sets, disposable syringes and plastic blood bags have obtained CE certification issued by t Ü vproductservicegmbh, the group has successively obtained disposable automatic blood collection sets, disposable CT enhanced syringe contrast agent syringes, disposable self destructed safety syringes and automatic retracted safety syringes CE certification of orthopedic instruments, metal plates, spine internal fixation system, metal screws, interlocking intramedullary nails, disposable sterile injection needles, disposable intravenous indwelling needles, needle free closed infusion joints and other products and systems. On December 5, 2003, the group's product quality inspection center was awarded the National Accreditation Committee of China laboratories as meeting the national testing and calibration regulations. On June 23, 2005, the trademark owned by the group was recognized by the State Administration for Industry and commerce as the first well-known trademark in China's domestic medical device industry. At present, the group's sales are mainly in the Chinese market, and the group is actively exploring the international market. Its products have been exported to 30 countries and regions such as the United States, Germany, Romania, Australia and the United Kingdom.

本文链接: https://brand.waitui.com/b82feb6b3.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

截至2025年末私募基金规模达22.15万亿元

中国基金业协会最新发布的数据显示,2025年12月,新备案私募基金数量2087只,新备案规模989.00亿元。截至2025年12月末,存续私募基金138315只,存续基金规模22.15万亿元。其中,存续私募证券投资基金80390只,存续规模7.08万亿元;存续私募股权投资基金29820只,存续规模11.19万亿元;存续创业投资基金27342只,存续规模3.58万亿元。

41分钟前

人工智能热潮引发存储芯片抢购 芯片短缺愈演愈烈

包括埃隆·马斯克、蒂姆·库克在内的科技行业领袖纷纷警告一场全球性危机正在酝酿:存储芯片短缺开始冲击利润、打乱企业规划,推高从笔记本电脑、智能手机到汽车和数据中心等各类产品的价格,而且供应紧张只会愈演愈烈。今年初以来,特斯拉、苹果等十多家大型企业暗示DRAM这种几乎所有科技产品都要用到的存储芯片严重短缺,势将制约生产。库克表示,这将压缩iPhone的利润率。美光科技称短缺程度“前所未见”。马斯克甚至表示特斯拉将不得不自建芯片工厂。“如果我们不建芯片工厂,就会遇到芯片瓶颈,”马斯克上月末表示。造成存储芯片供应紧张的根本原因在于人工智能(AI)数据中心的建设浪潮。由于英伟达的AI芯片需要配备大量高带宽内存,存储芯片行业的可用产能遭到挤占,以至用于手机、个人电脑等传统领域的存储芯片也面临严重短缺。Bernstein半导体行业分析师Mark Li警告称,内存价格正在呈现“抛物线式”上涨。虽然这将为三星、美光和SK海力士带来丰厚利润,但电子行业的其他领域将在未来数月付出沉重代价。

41分钟前

印度拟重振私人资本对高速公路的投资

印度正努力吸引私人资本重新进入公路建设领域。十年前,投资者因担忧收益风险与官僚审批拖延而纷纷撤离该领域。据知情人士透露,印度政府正制定新规,承诺为开发商提供收益保障,并邀请全球基金参与项目竞标,以加快高速公路建设。上述不愿具名的人士表示,该政策框架预计将于本月敲定,目标是在 2027 财年前向私营部门授予价值 1 万亿卢比(约 110 亿美元)的项目。他们还称,总理纳伦德拉・莫迪政府希望明年私人投资在公路建设中的占比最高达到25%,而目前这一比例仅为较低的个位数。

41分钟前

韩文秀:着力稳定房地产市场 积极有序化解地方政府债务风险

据求是网消息,中央财办分管日常工作的副主任、中央农办主任韩文秀发表文章《坚持稳中求进、提质增效努力实现“十五五”良好开局》。文章称,妥善做好重点领域风险化解,守住守牢安全底线。从房地产市场供需两端发力,因城施策控增量、去库存、优供给,着力稳定房地产市场,有序推动安全、舒适、绿色、智慧的“好房子”建设,以构建房地产发展新模式为牵引推动房地产高质量发展。积极有序化解地方政府债务风险,督促各地主动化债,严防虚假化债,不得违规新增隐性债务。优化债务重组和置换办法,多措并举化解地方政府融资平台经营性债务风险。稳妥推进地方中小金融机构风险化解、减量提质,充实风险处置资源和手段,强化早期干预和处置,牢牢守住不发生系统性风险的底线。

41分钟前

交通运输部发布2月9日—2月15日全国物流保通保畅运行情况

交通运输部发布2月9日—2月15日,全国物流保通保畅运行数据:国家铁路运输货物7357.4万吨,环比下降5.44%;全国高速公路货车通行3373.7万辆,环比下降40.04%;监测港口完成货物吞吐量23976.6万吨,环比下降5.39%,完成集装箱吞吐量647.5万标箱,环比下降4.66%;民航保障航班13.9万班(其中货运航班5315班,包括国际货运航班3380班,国内货运航班1935班),环比增长2.57%;邮政快递揽收量约22.83亿件,环比下降51.28%;投递量约33.28亿件,环比下降28.32%。

41分钟前

本页详细列出关于洁瑞的品牌信息,含品牌所属公司介绍,洁瑞所处行业的品牌地位及优势。
咨询